Home / Clinical Laboratory / Clinical Analyzer Calibrators and Reagents / Reagents / Reagent Kit / Reagent Kit AdviseDx Antibody Test SARS-CoV-2 IgM For use with Alinity i System 200 Tests 21 mL06R9120
Picture of Reagent Kit AdviseDx Antibody Test SARS-CoV-2 IgM For use with Alinity i System 200 Tests 21 mL06R9120

Reagent Kit AdviseDx Antibody Test SARS-CoV-2 IgM For use with Alinity i System 200 Tests 21 mL06R9120

Reagent-Kit-AdviseDx-Antibody-Test-SARS-CoV-2-IgM-For-use-with-Alinity-i-System-200-Tests-21-mL06R9120

SKU #

#1179185

MPN #

06R9120

Brand

Abbott

Stock

In Stock

Quantity

100

Features

REAGENT, SARS-COV-2 IGM ALINITY (200TEST/KT) D/S

$1,394.61 USD

Product Specifications Product Usage Additional Information
Print
Attribute Name Attribute Value
McKesson # 1179185
Manufacturer # 06R9120
Brand AdviseDx
Manufacturer Abbott
Application Reagent Kit
Container Type Cartridge
For Use With For use with Alinity i System
Number of Tests 200 Tests
Product Dating McKesson Acceptable Dating: we will ship >= 90 days
Sample Type Human Serum / Plasma Sample
Storage Requirements Requires Refrigeration
Test Name SARS-CoV-2 IgM
Test Type Antibody Test
Type Chemiluminescent Microparticle Immunoassay (CMIA)
UNSPSC Code 41116010
Volume 21 mL
Compare Selected Items Email

Similar Items

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

  • The AdviseDx SARS-CoV-2 IgM Assay is for use under an FDA EUA only: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations
  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C 263a, that meet requirements to perform moderate or high complexity tests
  • The AdviseDx SARS-CoV-2 IgM assay is a chemiluminescent microparticle immunoassay (CMIA) intended for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum, serum separator tube, and plasma (dipotassium EDTA, tripotassium EDTA, lithium heparin, lithium heparin separator tube, sodium heparin)
  • At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity; AdviseDx SARSCoV-2 IgM assay should not be used to diagnose acute SARS-CoV-2 infection
  • Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities
  • Negative results do not preclude acute SARSCoV-2 infection; if acute infection is suspected, direct testing for SARS-CoV-2 is necessary
  • False positive results for the AdviseDx SARS-CoV-2 IgM assay may occur due to cross-reactivity from pre-existing antibodies or other possible causes
  • Due to the risk of false positive results, confirmation of positive results should be considered using a second, different IgM assay